BRIEF published on 10/22/2024 at 18:05, 1 month ago ENOGIA wins key contract for supercritical CO2 power plant in South Korea Energy Transition ENOGIA South Korea Turbomachines Supercritical CO2
PRESS RELEASE published on 10/22/2024 at 18:00, 1 month ago ENOGIA: ENOGIA wins major supercritical CO₂ contract in South Korea ENOGIA wins major supercritical CO₂ contract in South Korea with Sunbo Unitech for a turbine in KEPCO project, driving green energy transition Renewable Energy Energy Transition ENOGIA South Korea Supercritical CO2
BRIEF published on 09/09/2024 at 07:50, 2 months 14 days ago ENOGIA Reports Strong First-Half 2024 Results with 53% Revenue Increase Revenue Increase Operational Efficiency ENOGIA EBITDA Breakeven 2025 Outlook
PRESS RELEASE published on 09/09/2024 at 07:45, 2 months 14 days ago ENOGIA: First-half 2024 results ENOGIA reports 53% revenue growth to €3.6 million in first-half 2024, with EBITDA breakeven. Confirms >50% growth target for 2024 and 2025 EBITDA Revenue Growth Financial Targets Energy Transition ENOGIA
BRIEF published on 07/22/2024 at 18:05, 4 months ago ENOGIA: Turnover for the first half of 2024: + 53% Growth Turnover ENOGIA Geothermal Energy Turbomachines
PRESS RELEASE published on 07/22/2024 at 18:00, 4 months ago ENOGIA: First-half 2024 revenue: +53% ENOGIA achieves a revenue growth of +53% in the first half of 2024 driven by key markets. Geothermal & marine energy sectors show strong momentum. Innovative Turbomachinery revenue up 385% Revenue Growth ENOGIA Innovative Turbomachinery Geothermal Energy Marine Energy
BRIEF published on 07/12/2024 at 16:55, 4 months 10 days ago Half-year review of the ENOGIA liquidity contract as of June 30, 2024 Liquidity Contract Transaction ENOGIA Marseille
BRIEF published on 03/27/2024 at 18:05, 7 months 26 days ago ENOGIA Reports Strong Financial Growth in 2023 Annual Results Financial Results Revenue Growth Operational Efficiency Energy Transition ENOGIA
PRESS RELEASE published on 03/27/2024 at 18:00, 7 months 26 days ago ENOGIA: 2023 annual results ENOGIA reports a 53% revenue growth in 2023, reaching €5.1 million. Targets >50% growth in 2024-2025 and breakeven EBITDA in 2024. Positive free cash flow expected by 2025 EBITDA Revenue Growth Free Cash Flow 2023 Annual Results ENOGIA
PRESS RELEASE published on 02/26/2024 at 18:00, 8 months 25 days ago ENOGIA: 2023 annual revenue: €5.1 million (+53%) ENOGIA reports 2023 annual revenue of €5.1 million, up 53% from 2022, with strong momentum in the ORC business and successful repositioning in turbomachinery development Energy Transition ENOGIA 2023 Annual Revenue Micro-turbomachinery ORC Business
Published on 11/22/2024 at 23:55, 9 hours 25 minutes ago Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 9 hours 50 minutes ago Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 10 hours 15 minutes ago Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 10 hours 50 minutes ago Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.
Published on 11/22/2024 at 18:14, 15 hours 5 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 17:53, 15 hours 26 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 16 hours 24 minutes ago EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 17 hours 19 minutes ago Proposed cancellation of admission to trading
Published on 11/21/2024 at 06:58, 2 days 2 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 2 days 14 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 2 days 15 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 2 days 15 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
